Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Titre officiel

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

Sommaire:

L’objectif de cette étude est d’évaluer l’innocuité et l’efficacité du nemtabrutinib (anciennement ARQ 531) chez des participants atteints d’affections malignes hématologiques telles que la leucémie lymphocytaire chronique (LLC)/le petit lymphome lymphocytaire (PLL), la transformation de Richter, le lymphome de la zone marginale (LZM), le lymphome à cellules du manteau (LCM), le lymphome folliculaire (LF) et la macroglobulinémie de Waldenström (MW).

Description de l'essai

Primary Outcome:

  • Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
  • Part 1: Number of participants experiencing adverse events (AEs)
  • Part 1: Number of participants discontinuing study treatment due to AEs
  • Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
  • Part 2: ORR per Lugano criteria 2014 as assessed by ICR
  • Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
Secondary Outcome:
  • Part 1: Area Under the Curve (AUC) of Nemtabrutinib
  • Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
  • Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
  • Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
  • Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
  • Part 2: Number of participants experiencing AEs
  • Part 2: Number of participants discontinuing study treatment due to AEs
  • Part 2: AUC of Nemtabrutinib
  • Part 2: Cmin of Nemtabrutinib
  • Part 2: Cmax of Nemtabrutinib
  • Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
  • Part 2: DOR per Lugano criteria 2014 as assessed by ICR
  • Part 2: DOR per IWWM criteria 2014 as assessed by ICR
This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of a recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer